• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Dupilumab reduces systemic glucocorticoid use in severe asthmatics

byDayton McMillan
July 3, 2018
in Chronic Disease, Emergency, Pediatrics, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Glucocorticoid dependent severe asthmatics treated with dupilumab for 24 weeks used significantly lower doses of glucocorticoids while maintaining asthmatic control compared to placebo treated patients.

2. Dupilumab treated patients experienced lower rates of severe asthma exacerbations compared to those treated with placebo.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: Patients with severe asthma often utilize systemic glucocorticoids to reduce respiratory inflammation. These agents are nonselective, associated with numerous side effects, and are immunosuppressive. Type 2 inflammation involved in asthma can be more selectively targeted through the interleukin-4 receptor. The monoclonal antibody dupilumab has been used to reduce type 2 inflammation in other inflammatory conditions and has potential to be used in glucocorticoid depended severe asthmatics to reduce glucocorticoid use. This phase 3 randomized study, the LIBERTY ASTHMA VENTURE trial, treated patients with dupilumab and placebo for 24 weeks and found a significant reduction in glucocorticoid use in the dupilumab group, all while asthmatic symptom control was maintained. Dupilumab treated patients also had a lower rate of severe asthma exacerbations and a higher forced expiratory volume in 1 second (FEV1) than those in the placebo group.

Strengths of this study included evaluation of laboratory inflammation markers in addition to clinical markers of efficacy and strong subgroup outcomes analysis. Limitations include a short evaluation period and lack of discussion of treatment cost.

Click to read the study, published in NEJM

Relevant Reading: Dupilumab treatment in adults with moderate-to-severe atopic dermatitis

RELATED REPORTS

Wellness Check: Sleep

Dupilumab improves symptoms and increases remission rates in eosinophilic esophagitis

Emergency department crowding negative influences outcomes for adults presenting with asthma

In-Depth [randomized controlled trial]: This phase 3 randomized controlled trial was conducted between 2015 and 2017. Eligible patients were 12 or older and had been receiving systemic glucocorticoids for last 6 months for diagnosed asthma. Patients were randomized to a dupilumab group (n = 103) who received subcutaneous dupilumab biweekly for 24 weeks or a placebo group (n = 107). Glucocorticoids were reduced until they had an increase of 0.5 on the Asthma Control Questionnaire (ACQ-5), a severe exacerbation, or a clinical need for increased glucocorticoids. The primary end-point was percent reduction from baseline to week 24 of glucocorticoid dose while asthma control was maintained. Key secondary outcomes included proportion of patients with at least a 50% reduction in glucocorticoid dose and proportion of patients who used a minimal dose of systemic glucocorticoids.

Glucocorticoids were reduced in the treatment group by 70.1% and in the placebo group by 41.9% (p < 0.001). Reduction in glucocorticoid use by 50% or more occurred in 80% of treatment and 50% of placebo patients (p < 0.001) and use of less than 5mg prednisone a day occurred in 69% of the treatment and 33% of the placebo groups (p < 0.001). Dupilumab was associated with a 59% lower rate of severe asthma exacerbations (95% confidence interval [CI], 37 to 74). FEV1 was an average of 0.22 liters (95% CI, 0.09 to 0.34) higher in the treatment group. Adverse events occurred at similar rates between the two trial groups, with serious adverse events occurring in 9% of treatment and 6% of placebo patients.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: asthmacorticosteroidsdupilumab
Previous Post

2 Minute Medicine Rewind July 2, 2018

Next Post

Enzalutamide reduces risk of metastatic prostate cancer in at-risk men

RelatedReports

Decline in adolescent sleep duration over past 20 years
Wellness

Wellness Check: Sleep

January 19, 2023
Extensive lymphadenectomy may not increase patient survival with esophageal cancer
Chronic Disease

Dupilumab improves symptoms and increases remission rates in eosinophilic esophagitis

January 9, 2023
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Emergency

Emergency department crowding negative influences outcomes for adults presenting with asthma

December 27, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Overprescribed and Understocked, A Costly Message, A Bad Wrap and Mauna Loa Erupts Again!

December 14, 2022
Next Post
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Enzalutamide reduces risk of metastatic prostate cancer in at-risk men

Family-support intervention does not significantly improve surrogates’ psychological symptoms: The PARTNER trial

Maternal vaccination during pregnancy not associated with infant hospitalization, mortality

Women who experience hypertensive disorders during pregnancy are at high risk for developing high blood pressure, diabetes, and high cholesterol later in life

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options